Cargando…

Ixazomib for Desensitization (IXADES) in Highly Sensitized Kidney Transplant Candidates: A Phase II Clinical Trial

KEY POINTS: Ixazomib treatment resulted in decreases in B-cell subsets and bone marrow lymphocytes. Ixazomib treatment resulted in modest decreases in certain anti-HLA antibody specificities. Ixazomib treatment was tolerated, with modest adverse events. BACKGROUND: Ixazomib is a second-generation or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Nancy, Reese, Shannon, Ptak, Lucy, Aziz, Fahad, Parajuli, Sandesh, Jucaud, Vadim, Denham, Shari, Mishra, Ameet, Cascalho, Marilia, Platt, Jeffrey L., Hematti, Peiman, Djamali, Arjang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Nephrology 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371382/ https://www.ncbi.nlm.nih.gov/pubmed/36951387 http://dx.doi.org/10.34067/KID.0000000000000113

Ejemplares similares

Unusually high rates of acute rejection during the COVID-19 pandemic: cause for concern?
por: Aziz, Fahad, et al.
Publicado: (2020)

How Should Acute T-cell Mediated Rejection of Kidney Transplants Be Treated: Importance of Follow-up Biopsy
por: Aziz, Fahad, et al.
Publicado: (2022)

Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2019)

The care of kidney transplant recipients during a global pandemic: Challenges and strategies for success
por: Aziz, Fahad, et al.
Publicado: (2020)

Role of novel biomarkers in kidney transplantation
por: Swanson, Kurtis J, et al.
Publicado: (2020)

Early Report on Published Outcomes in Kidney Transplant Recipients Compared to Nontransplant Patients Infected With Coronavirus Disease 2019
por: Aziz, Fahad, et al.
Publicado: (2020)

Treatment of Chronic Active Antibody-mediated Rejection With Pulse Steroids, IVIG, With or Without Rituximab is Associated With Increased Risk of Pneumonia
por: Joachim, Emily, et al.
Publicado: (2020)

Significance of Asymptomatic Pyelonephritis Found on Kidney Transplant Biopsy
por: Aziz, Fahad, et al.
Publicado: (2021)

Glomerular C3 Deposition Is an Independent Risk Factor for Allograft Failure in Kidney Transplant Recipients With Transplant Glomerulopathy
por: Panzer, Sarah E., et al.
Publicado: (2019)

Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients: Treatment Response Rates and Value of Early Surveillance Biopsies
por: Aziz, Fahad, et al.
Publicado: (2022)

Modest Improvements in Refractory Antibody-Mediated Rejection After Prolonged Treatment
por: Degner, Kenna R., et al.
Publicado: (2021)

Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation
por: Parajuli, Sandesh, et al.
Publicado: (2017)

Continuation of Peritoneal Dialysis in Adult Kidney Transplant Recipients With Delayed Graft Function
por: Gardezi, Ali I., et al.
Publicado: (2021)

Pneumocystis jiroveci pneumonia in kidney and simultaneous pancreas kidney transplant recipients in the present era of routine post-transplant prophylaxis: risk factors and outcomes
por: Garg, Neetika, et al.
Publicado: (2018)

Pancreas Retransplant After Pancreas Graft Failure in Simultaneous Pancreas-kidney Transplants Is Associated With Better Kidney Graft Survival
por: Parajuli, Sandesh, et al.
Publicado: (2019)

IgM in the Kidney: A Multiple Personality Disorder
por: Platt, Jeffrey L., et al.
Publicado: (2015)

Cell Fusion in Malignancy: A Cause or Consequence? A Provocateur or Cure?
por: Platt, Jeffrey L., et al.
Publicado: (2019)

Challenges and potentials of xenotransplantation
por: Cascalho, Marilia, et al.
Publicado: (2008)

TNFRSF13B Diversification Fueled by B Cell Responses to Environmental Challenges—A Hypothesis
por: Cascalho, Marilia, et al.
Publicado: (2021)

TNFRSF13B in B cell responses to organ transplantation
por: Cascalho, Marilia, et al.
Publicado: (2023)

Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure
por: Parajuli, Sandesh, et al.
Publicado: (2019)

Mycophenolate Monotherapy in HLA-Matched Kidney Transplant Recipients: A Case Series of 20 Patients
por: Hennes, Anthony J., et al.
Publicado: (2020)

Histopathological characteristics and causes of kidney graft failure in the current era of immunosuppression
por: Parajuli, Sandesh, et al.
Publicado: (2019)

Incidence and Outcomes of Significant Weight Changes After Pancreas Transplant Alone
por: Swanson, Kurtis J., et al.
Publicado: (2020)

The Pin 1 inhibitor juglone attenuates kidney fibrogenesis via Pin 1-independent mechanisms in the unilateral ureteral occlusion model
por: Reese, Shannon, et al.
Publicado: (2010)

Regional delivery of immunosuppression for transplantation of vascularized composite allografts: opportunities near and far
por: Platt, Jeffrey L., et al.
Publicado: (2021)

Sweet Syndrome Associated with Ixazomib
por: Yavaşoğlu, İrfan, et al.
Publicado: (2021)

Ixazomib-Associated Skin Exfoliation
por: Zhang, Yali, et al.
Publicado: (2022)

The Immunogenicity of HLA Class II Mismatches: The Predicted Presentation of Nonself Allo-HLA-Derived Peptide by the HLA-DR Phenotype of the Recipient Is Associated with the Formation of DSA
por: Jucaud, Vadim
Publicado: (2017)

Autologous Mesenchymal Stromal Cells Prevent Transfusion-elicited Sensitization and Upregulate Transitional and Regulatory B Cells
por: Zhang, Zijian, et al.
Publicado: (2018)

Cell Fusion in the War on Cancer: A Perspective on the Inception of Malignancy
por: Platt, Jeffrey L., et al.
Publicado: (2016)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
por: Kumar, Shaji K., et al.
Publicado: (2019)

Effects of Oxidative Stress on Mesenchymal Stem Cell Biology
por: Denu, Ryan A., et al.
Publicado: (2016)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
por: Muz, Barbara, et al.
Publicado: (2016)

T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
por: Haq, M., et al.
Publicado: (2021)

Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target
por: Vidyasagar, Aparna, et al.
Publicado: (2012)

The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis
por: Danobeitia, Juan S, et al.
Publicado: (2014)

Tubular expression of heat shock protein 27 inhibits fibrogenesis in obstructive nephropathy
por: Vidyasagar, Aparna, et al.
Publicado: (2012)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
por: Li, Shutan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7vskbqnm5tpadhepoptlg2dpor